ArticleFrontiers in pharmacology2023
Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with
Ling Yu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.